NCT05727215View on ClinicalTrials.gov

Heterologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine in Children 12-17 Years of Age

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

February 28, 2023

Primary Completion Date

February 22, 2024

Study Completion Date

March 18, 2024

Conditions
COVID-19
Interventions
BIOLOGICAL

SARS-CoV-2 subunit protein recombinant vaccine

SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma

Trial Locations (1)

40161

Faculty of Medicine Universitas Padjadjaran, Bandung

Sponsors

Lead Sponsor

PT Bio Farma
All Listed Sponsors
collaborator

Universitas Padjadjaran

OTHER

lead

PT Bio Farma

INDUSTRY

NCT05727215 - Heterologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine in Children 12-17 Years of Age | Biotech Hunter | Biotech Hunter